-
1
-
-
0028956045
-
Fluorouracil plus levamisole as effective adjuvant therapy after resection in stage III colon carcinoma: A final report
-
Moertel CG, Fleming TR, MacDonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection in stage III colon carcinoma: A final report. Ann Intern Med 122: 321-326.
-
Ann Intern Med
, vol.122
, pp. 321-326
-
-
Moertel, C.G.1
Fleming, T.R.2
MacDonald, J.S.3
-
2
-
-
0024347268
-
Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
-
Poon MA, O'Connell W, Moertel CG et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-1418.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1407-1418
-
-
Poon, M.A.1
O'Connell, W.2
Moertel, C.G.3
-
3
-
-
0027436244
-
The benefit of leucovorin modulated fluorouracil as post operative adjuvant therapy for primary colon cancer: Results from NSABP c-03
-
Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin modulated fluorouracil as post operative adjuvant therapy for primary colon cancer: Results from NSABP c-03. J Clin Oncol 1993; 11: 1879-1887.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1879-1887
-
-
Wolmark, N.1
Rockette, H.2
Fisher, B.3
-
4
-
-
0042887580
-
Semimonthly versus monthly regimen of fluorouracil and leucovorin administred for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial
-
Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administred for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 2003; 21: 2896-2903.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2896-2903
-
-
Andre, T.1
Colin, P.2
Louvet, C.3
-
5
-
-
2542615200
-
Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer
-
Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
-
(2004)
N Engl J Med
, vol.350
, pp. 2343-2351
-
-
Andre, T.1
Boni, C.2
Mounedji-Boudiaf, L.3
-
6
-
-
24344476396
-
A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07
-
Abstr 3500
-
Wolmark N, Wieand HS, Kuebler JP. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 2005; Abstr 3500.
-
(2005)
Proc Am Soc Clin Oncol
-
-
Wolmark, N.1
Wieand, H.S.2
Kuebler, J.P.3
-
7
-
-
21344456269
-
Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid(IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)
-
Abstr 8
-
Van Cutsem E, Labianca R, Hossfeld D et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid(IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Proc Am Soc Clin Oncol 2005; 23: Abstr 8.
-
(2005)
Proc Am Soc Clin Oncol
, vol.23
-
-
Van Cutsem, E.1
Labianca, R.2
Hossfeld, D.3
-
8
-
-
9144238357
-
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial
-
Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
-
(2003)
Ann Oncol
, vol.14
, pp. 1735-1743
-
-
Scheithauer, W.1
McKendrick, J.2
Begbie, S.3
-
9
-
-
10644243163
-
A phase III trial omparing oral UFT to FULV in stage II and III carcinomaof colon: Results of NSABP C-06
-
Abstr 3508
-
Wolmark N, Wieand S, Lembersky B et al. A phase III trial omparing oral UFT to FULV in stage II and III carcinomaof colon: Results of NSABP C-06. Proc Am Soc Clin Oncol 2004; 23: Abstr 3508.
-
(2004)
Proc Am Soc Clin Oncol
, vol.23
-
-
Wolmark, N.1
Wieand, S.2
Lembersky, B.3
-
10
-
-
33745598215
-
Meta-Analysis Group in Cancer (MAGIC) Progression-Free Survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials
-
Abstr 3513
-
Buyse M, Burzykowski T, Carroll K et al. Meta-Analysis Group in Cancer (MAGIC) Progression-Free Survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials. Proc Am Soc Clin Oncol 2005; 23: Abstr 3513.
-
(2005)
Proc Am Soc Clin Oncol
, vol.23
-
-
Buyse, M.1
Burzykowski, T.2
Carroll, K.3
-
11
-
-
33644834827
-
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
-
Sargent DJ, Wieand S, Benedetti J et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8664-8670
-
-
Sargent, D.J.1
Wieand, S.2
Benedetti, J.3
|